In this new study, Thomas Seyfried and colleagues used nutritional ketosis to improve treatment outcomes in pediatric high-grade glioma, one of the deadliest childhood cancers. Using juvenile mouse models, the researchers combined a ketogenic diet with two drugs—mebendazole, an antiparasitic drug with anticancer properties, and devimistat (CPI-613), a metabolic therapy that targets mitochondrial fuel utilization. The ketogenic diet consistently enhanced the effectiveness of both drugs, leading to slower tumor progression, reduced invasion into the brain and spinal cord, and longer survival than drug treatment alone.

The findings support the view that glioma cells depend heavily on glucose and glutamine metabolism because of impaired mitochondrial energy production. By lowering glucose availability and increasing circulating ketones, the ketogenic diet created metabolic stress that made tumor cells more vulnerable to therapies targeting glycolysis and glutaminolysis. The diet also improved drug delivery and allowed lower doses to achieve therapeutic effects, reducing toxicity while maintaining efficacy.

The authors describe this as a "press-pulse" strategy, where a ketogenic diet provides continuous metabolic pressure while targeted therapies exploit specific metabolic vulnerabilities in cancer cells. Although the work was conducted in animal models rather than human patients, it adds to a growing body of evidence showing that ketogenic therapy can enhance the effectiveness of cancer treatment while reducing side effects.